semaglutide banned in california Novo Nordisk asks FDA to ban compounded Ozempic, Wegovy copies FDA issued 25 warning letters

Expand therapeutic use By focusing on health optimization rather than disease treatment, microdosing opens up possibilities for a broader range of patients

How It Works Complete a free online evaluation

Your clinician can help determine whether dry mouth is truly related to semaglutide, investigate alternative causes, adjust your treatment regimen if necessary, or provide additional management strategies

Food and Drug Administration (FDA) approved semaglutide (Wegovy) for chronic weight management in adults with obesity or overweight individuals who have at least one weight-related health condition, such as hypertension, type 2 diabetes, or high cholesterol

Body mass index is only one screening measure, but it can help frame weight-related discussions with a clinician

Weight loss continues but gradually slows